Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

New Program Aids Physicians Identify Gene-Drug Interactions

By BiotechDaily International staff writers
Posted on 23 Apr 2013
A data management and analysis platform gives doctors real-time therapeutic and diagnostic guidance, based on the patient’s genetic profile.

Developed by researchers at Mount Sinai Medical Center (MSMC; New York, NY, USA), the revolutionary platform communicates with the MSMC electronic health record (EHR). MSMC is pilot testing the platform through the CLinical Implementation of Personalized Medicine through Electronic health Records and Genomics (CLIPMERGE) research program. Once a patient has consented to take part in CLIPMERGE, their DNA is analyzed for genetic variations, which are stored on the platform, and remain there until the patient is prescribed a medication for which CLIPMERGE holds genomically relevant information.

Such information could include a lower likelihood of the drug being effective, or there being a higher chance of side effects due to that patient’s particular type of genetic variation. When this happens, CLIPMERGE displays an alert on the EHR screen and sends a message, in real time, to the attending physician, consisting of text describing the reason for the alert, some suggestions of alternative medications or doses that could be used, and a link to reference material so that physicians can read more about the science and evidence for pharmacogenomics. A study describing CLIPMERGE will be published in the August 2013 issue of Clinical Pharmacology and Therapeutics.

“Our knowledge of pharmacogenomics, or genome-drug interactions, and how genetics can influence why some patients react better to some drugs than others, is growing rapidly, and will likely transform how drugs are prescribed in the future,” said lead author Omri Gottesman, MD. “We hope that through CLIPMERGE, we can establish best practices both technological and human; and a robust process for clinical-decision support to deliver relevant genomic information to physicians at the moment they are caring for patients.”

Beyond the 1,500 patients enrolled in the pilot project, Mount Sinai has also enrolled since 2007 a total of 25,000 patients in the BioMe Biobank, one of the largest genetic repositories in the United States. The combination of BioMe and CLIPMERGE allows feedback on optimal therapeutics for multiple conditions related to cardiovascular disease, blood clots, high cholesterol, depression, and pain, based on a patient’s DNA, and is an important step forward on the road to personalized medicine.

“Enrolling this number of patients is a significant achievement for Mount Sinai and combined with programs such as CLIPMERGE, is propelling us to the forefront of precision medicine and its application in the clinical setting,” said Dennis Charney, MD, executive vice president for academic affairs of The MSMC. “The future of medicine lies in genomics research and translating it to the bedside—and Mount Sinai’s commitment to translational research makes us uniquely poised to lead that revolution.”

Related Links:

Mount Sinai Medical Center





comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.